Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | DGKA | P23743 | 2/20 | 0.53 |
| ▸ | PRKCA | P17252 | 3/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4895593 | 1.00 | MAPT (0.78) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL8950262 | 1.00 | MAPT (0.78) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL1173113 | 1.00 | MAPT (0.78) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL17668918 | 1.00 | MAPT (0.78) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL323988 | 1.00 | MAPT (0.78) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL15665486 | 1.00 | MAPT (0.78) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL15665017 | 1.00 | MAPT (0.78) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL630648 | 0.98 | MAPT (0.76) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL10674380 | 0.98 | MAPT (0.76) | MAPTLMNAKDM4EDUSP3MEN1 | |
| SCHEMBL10673541 | 0.98 | MAPT (0.76) | MAPTLMNAKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62242647-A | — | — | None | — | — | JP | disclosed |
| EP-3795141-B1 | SOLID SOLUTION COMPOSITIONS | INFIRST HEALTHCARE LTD (GB) | 2025-07-30 | — | — | EP | disclosed |
| US-20240277613-A1 | Solid Solution Compositions and Use in Chronic Inflammation | INFIRST HEALTHCARE LIMITED (GB) | 2024-08-22 | — | — | US | disclosed |
| US-20240207408-A1 | Solid Solution Compositions and Use in Severe Pain | INFIRST HEALTHCARE LIMITED (GB) | 2024-06-27 | — | — | US | disclosed |
| US-11992555-B2 | Solid solution compositions and use in chronic inflammation | INFIRST HEALTHCARE LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-11918654-B2 | Solid solution compositions and use in severe pain | INFIRST HEALTHCARE LIMITED (GB) | 2024-03-05 | — | — | US | disclosed |
| US-11844773-B2 | Solid solution compositions and use in chronic inflammation | INFIRST HEALTHCARE LIMITED (GB) | 2023-12-19 | — | — | US | disclosed |
| US-11826428-B2 | Solid solution compositions comprising cannabidiols | INFIRST HEALTHCARE LIMITED (GB) | 2023-11-28 | — | — | US | disclosed |
| US-11730709-B2 | Compositions and methods for treating severe pain | INFIRST HEALTHCARE LIMITED (GB) | 2023-08-22 | — | — | US | disclosed |
| US-20220118091-A1 | Solid Solution Compositions and Use in Severe Pain | INFIRST HEALTHCARE LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| WO-2014108572-A1 | SOLID SOLUTION COMPOSITIONS AND USE IN CARDIOVASCULAR DISEASE | BIOCOPEA LIMITED (GB) | 2014-07-17 | — | — | WO | disclosed |
| US-20140199296-A1 | Cancer Drug and Uses | BIOCOPEA LIMITED (GB) | 2014-07-17 | — | — | US | disclosed |
| WO-2014108573-A1 | SOLID SOLUTION COMPOSITIONS AND USE IN CHRONIC INFLAMMATION | BIOCOPEA LIMITED (GB) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014108571-A2 | CANCER DRUG AND USES | BIOCOPEA LIMITED (GB) | 2014-07-17 | — | — | WO | disclosed |
| US-20140162988-A1 | Solid Solution Compositions and Use in Chronic Inflammation | BIOCOPEA LIMITED (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140162987-A1 | Solid Solution Compositions and Use in Severe Pain | BIOCOPEA LIMITED (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140155485-A1 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases | BIOCOPEA LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140128353-A1 | Solid Solution Compositions and Use in Cardiovascular Disease | BIOCOPEA LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| US-20140128354-A1 | Compositions and Methods for Treating Severe Pain | BIOCOPEA LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| JP-S62242647-A | NOVEL ESTER AND COSMETIC CONTAINING SAME | NISSHIN OIL MILLS LTD:THE | 1987-10-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199296-A1 | Cancer Drug and Uses | NPC1L1, PCK2, NPC1 | MAPT 716/4885LMNA 2823/4885KDM4E 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.